 ROCKVILLE, Md., Oct. 25, 2022 GLOBE NEWSWIRE -- Supernus Pharmaceuticals, Inc. Nasdaq: SUPN, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system CNS diseases, today announced that the Company expects to report financial and business results for the third quarter of 2022 after the market closes on Tuesday, November 8, 2022. 